Unique ID issued by UMIN | UMIN000000961 |
---|---|
Receipt number | R000001156 |
Scientific Title | Feasibility study of neoadjuvant chemotheray mFOLFOX6 for resectable liver metastases of colorectal cancers |
Date of disclosure of the study information | 2008/01/07 |
Last modified on | 2012/01/06 12:07:30 |
Feasibility study of neoadjuvant chemotheray mFOLFOX6 for resectable liver metastases of colorectal cancers
Feasibility study of neoadjuvant chemotheray mFOLFOX6 for resectable liver metastases of colorectal cancers
Feasibility study of neoadjuvant chemotheray mFOLFOX6 for resectable liver metastases of colorectal cancers
Feasibility study of neoadjuvant chemotheray mFOLFOX6 for resectable liver metastases of colorectal cancers
Japan |
colorectal cancers
Gastrointestinal surgery | Hepato-biliary-pancreatic surgery |
Malignancy
NO
To evaluate the safety of liver resection for metastatic lesions from colorectal cancers after neoadjuvant chemotherapy (mFOLFOX6)
Safety
Curative resection rates of liver metastases
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
Surgery
20 | years-old | <= |
80 | years-old | >= |
Male and Female
1) Histologically diagnosed as colorectal adenocarcinomas, including cecal, appendecal, and anal canal cancers.
2) Liver lesions are measurable by spiral CT or SPIO-MRI scans.
3) Extrahepatic lesions include lung metastases which can be resected curatively.
4) Curative resection for metastatic lesions can be performed with residual hepatic functions preserved.
5) No prior treatment histories for liver lesions, including L-OHP regimens, hepatectomy, hepatic arterial infusion, MCT, or RFA
6) No evidence of chronic hepatic diseases which affect systemic chemotherapy and/or surgical resection
7) Performance status (ECOG): 0-1
8) Vital organ functions, including hematopoietic, cardiac, respiratory and renal functions, are preserved.
Excluded are cases with conditions as below:
1) Peritoneal or pleural fluid retention to be drainaged.
2) Multiple malignancies to be treated.
3) Peripheral neural disturbances.
4) Active infectious diseases.
5) Severe watery diarrhea.
6) Mental disturbances.
7) Treatment history of continuous, oral or intravenous steroid therapy.
8) Previous history of ischemic heart diseases.
9) Coexistent severe diseases including pulmonary fibrosis, interstitial pneumonia, ileus, uncontrollable diabetes, cardiac dysfunction, hepatic failure, or renal failure.
10) Pregnant.
11) Previous history of severe drug-induced allergy.
27
1st name | |
Middle name | |
Last name | Satoshi Nagayama |
Kyoto Univ Hospital
Surgery
54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto City
1st name | |
Middle name | |
Last name |
Kyoto Univ Hospital
Surgery
075-751-3227
Dept. Surgey
Kyoto University Hospital
Dept. Surgey
Kyoto University Hospital
Self funding
NO
2008 | Year | 01 | Month | 07 | Day |
Unpublished
2007 | Year | 12 | Month | 25 | Day |
2008 | Year | 01 | Month | 01 | Day |
2013 | Year | 01 | Month | 01 | Day |
2007 | Year | 12 | Month | 30 | Day |
2012 | Year | 01 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001156